TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Down 11.2% in February

TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Rating) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 239,000 shares, a decline of 11.2% from the February 13th total of 269,000 shares. Based on an average trading volume of 124,700 shares, the days-to-cover ratio is currently 1.9 days. Approximately 2.7% of the company’s shares are sold short.

Institutional Investors Weigh In On TherapeuticsMD

A number of hedge funds have recently added to or reduced their stakes in TXMD. Principal Financial Group Inc. increased its holdings in TherapeuticsMD by 6.3% in the first quarter. Principal Financial Group Inc. now owns 123,319 shares of the company’s stock worth $47,000 after purchasing an additional 7,263 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of TherapeuticsMD by 22.6% during the first quarter. JPMorgan Chase & Co. now owns 255,249 shares of the company’s stock valued at $97,000 after acquiring an additional 46,974 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of TherapeuticsMD by 4.8% during the first quarter. Rhumbline Advisers now owns 312,526 shares of the company’s stock valued at $119,000 after acquiring an additional 14,372 shares in the last quarter. UBS Group AG increased its holdings in shares of TherapeuticsMD by 258.1% during the second quarter. UBS Group AG now owns 18,133 shares of the company’s stock valued at $180,000 after acquiring an additional 13,069 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of TherapeuticsMD during the fourth quarter valued at approximately $249,000. 22.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of TherapeuticsMD in a research note on Wednesday, January 11th.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $3.88 on Monday. The company has a market cap of $36.55 million, a P/E ratio of -2.71 and a beta of 1.20. The stock has a 50 day simple moving average of $5.19 and a two-hundred day simple moving average of $5.79. TherapeuticsMD has a fifty-two week low of $1.99 and a fifty-two week high of $23.00.

TherapeuticsMD Company Profile

(Get Rating)

TherapeuticsMD, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm’s technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.